Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review
Background: PARP inhibitors have shown significant improvement in progression-free survival, but their costs cast a considerable financial burden. In line with value-based oncology, it is important to evaluate whether drug prices justify the outcomes.Objectives: The aim of the study was to systemati...
Saved in:
Main Authors: | Vivien Kin Yi Chan (Author), Runqing Yang (Author), Ian Chi Kei Wong (Author), Xue Li (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
by: Ruihong Dong, et al.
Published: (2023) -
Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer
by: Chia-Hao Liu, et al.
Published: (2017) -
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
by: Stephen A. Jannetti, et al.
Published: (2020) -
Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
by: Qin Xu, et al.
Published: (2021) -
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
by: Stergios Boussios, et al.
Published: (2020)